This website is certified by Health On the Net Foundation. Click to verify.

This site complies with the HONcode standard for trustworthy health information: verify here.


           Website Last update: 10/13/2015



 

EUROGIN e-Congress


The Best of EUROGIN 2015 Congress
aims at developing a full review of current scientific developments in the field of cervical cancer and human papillomavirus related diseases, raising the public health profile and increasing the need for clinicians,researchers and  responsible health services in the field.

The event endeavors to translate scientific and evidence-based research into clinical practice while highlighting the following aspects:

  • Recent advances and updated scientific insights in HPV screening, testing and management
  • The impact of HPV and associated cancers on public health
  • Strategies to prevent and treat HPV related diseases
  • Exchanging information on early detection, new diagnostic and therapeutic procedures and prevention strategies including screening and HPV vaccination

Speakers include international leaders from academic, government and private organizations, representatives of medical and scientific societies, as well as women's health associations who will discuss and exchange ideas on issues relevant to both individuals and public health.

[ Target Audience ]
[ Program Objectives ]
[ Format ]



[ Elearning Platform Process ]





[ Topics ]


Buy an access to the
12 Courses for 1 Month



Course I
From infection to diseases at different anatomic sites
Buy an access only to the
Course I for 1 Month
01

Length: 18.15 min

Epidemiology, transmission & natural history
A. Giuliano (USA)


Content: Biography, Abstract, Video

View the first minute

02

Length: 18.48 min

HPV immunology: an update
T.C. Wu (USA)


Content: Abstract, Video, Powerpoint

View the first minute



Course II
New strategies & innovations in cervical cancer control
Buy an access only to the
Course II for 1 Month
03

Length: 17.19 min

New standarts for HPV-based cervical cancer screening
E. Franco (Canada)

Content: Biography, Abstract, Video, Powerpoint

View the first minute

04

Length: 17.21 min

HPV prophylactic vaccines: lessons learned from 10 years experiances
J. Brotherton (Australia)

Content: Biography, Abstract, Video, Powerpoint

View the first minute

05

Length: 19.47 min

Integrating primary & secondary prevention: new strategies for cervical cancer control LIC vs HIC
P. Gravitt (USA)

Content: Biography, Abstract, Video, Powerpoint

View the first minute

06

Length: 17.06 min

Challenges facing novel HPV multivalent vaccine
E. Joura (Austria)

Content: Biography, Abstract, Video, Powerpoint

View the first minute

07

Length: 24.57 min

The expectancy of HPV therapeutic vaccine
M. Stanley (UK)

Content: Biography, Video, Powerpoint

View the first minute



Course III
Management of HPV cervical diseases - the state of the art
Buy an access only to the
Course III for 1 Month
08

Length: 20.35 min

The risk-based management
M. Stoler (USA)

Content: Biography, Abstract, Video, Powerpoint

View the first minute

09

Length: 14.44 min

Post-treatment surveillance options
M. Arbyn (Belgium)

Content: Biography, Video, Powerpoint

View the first minute

10

Length: 11.48 min

Discussion

Content: Video

View the first minute



Course IV
HPV-associated diseases in non-cervical sites - what the clinician schould know
Buy an access only to the
Course IV for 1 Month
11

Length: 14.03 min

Comparative epidemiology and HPV transmission by gender
A Giuliano (USA)

Content: Biography, Abstract, Video, Powerpoint

View the first minute

12

Length: 18.28 min

Current developments on HPV-caused oropharyngeal cancer
M. Gillison (USA)

Content: Video, Powerpoint

View the first minute

13

Length: 17.08 min

Clinical issues related to anal HPV infection and cancer
C. Fairley (Australia)

Content: Abstract, Video, Powerpoint

View the first minute



Course V
How to introduce HPV testing into primary screening?
Buy an access only to the
Course V for 1 Month
14

Length: 13.10 min

Ages for HPV screening: when to start, when to stop?
E. Franco (Canada)

Content: Biography, Abstract, Video, Powerpoint

View the first minute

15

Length: 11.59 min

What to do if HPV negative? Interval of screening 
J. Dillner (Sweden)

Content: Biography, Abstract, Video, Powerpoint

View the first minute

16

Length: 16.39 min

Impact of vaccination on primary HPV screening
X. Bosch (Spain)

Content: Biography, Video, Powerpoint

View the first minute



Course VI
Surveillance and impact of HPV prophylactic vaccines in population: current picture
Buy an access only to the
Course VI for 1 Month
17

Length: 14.52 min

Vaccine uptake accross the world
P. Bloem (Switzerland)

Content: Abstract, Video, Powerpoint

View the first minute

18

Length: 11.52 min

Monitoring impact in population
D. Mesher (UK)

Content: Abstract, Video, Powerpoint

View the first minute

19

Length: 12.13 min

Changes in disease prevalence in vaccinated women: Genital warts
L. Arnheim-Dahlström (Sweden)

Content: Abstract, Video, Powerpoint

View the first minute

20

Length: 13.01 min

Cancer registries: up to the task of monitoring post vaccination reductions in HPV-related cancers?
F. Bray (France)

Content: Video

View the first minute

21

Length: 9.51 min

Monitoring of RRP in the post vaccine era
P. Campisi (Canada)

Content: Abstract, Video, Powerpoint

View the first minute

22

Length: 11.54 min

Long-term efficacy of HPV vaccination against hard endpoints
J. Paavonen (Finland)

Content: Abstract, Video, Powerpoint

View the first minute



Course VII
Immunotherapy of HPV-associated diseases
Buy an access only to the
Course VII for 1 Month
23

Length: 11.40 min

Optimization and development of a therapeutic anti-HPV vaccine in Ear, Nose, Throat (ENT) cancer
C. Badoual (France)

Content: Abstract, Video, Powerpoint

View the first minute

24

Length: 13.40 min

Protease inhibitor in treatment of CIN
I. Hampson (UK)

Content: Abstract, Video, Powerpoint

View the first minute

25

Length: 7.51 min

Human papilloma viral clearance following HPV targeted immunotherapy, tipapkinogen Sovacivec, in patients with high grade CIN
D. Harper (USA)

Content: Abstract, Video, Powerpoint

View the first minute



Course VIII
New challenges facing HPV 16 & 18 infection
Buy an access only to the
Course VIII for 1 Month
26

Length: 13.56 min

HPV 16 &18 prevalence and burden of associated cancers
G Clifford (France)

Content: Biography, Video, Powerpoint

View the first minute

27

Length: 13.48 min

Assessing cancer risk of HPV 16 &18 infection
E. Franco (Canada)


Content: Biography, Abstract, Video, Powerpoint

View the first minute

28

Length: 13.56 min

Immune responses, regression and persistence of HPV 16 & 18
A.B. Moscicki (USA)

Content: Biography, Video, Powerpoint

View the first minute

29

Length: 12.44 min

Immune responses to HPV therapeutic vaccines
T.C. Wu (USA)

Content: Abstract, Video, Powerpoint

View the first minute

30

Length: 9.48 min

New paradigms of HPV 16 & 18 associated cancer control, the respective role ofprevention, screeningandimmunotherapy
M. Brisson (Canada)

Content: Biography, Video

View the first minute



Course IX
Moving from cyto to HPV-based primary screening - Mutualizing experiances / implementation issues
Buy an access only to the
Course IX for 1 Month
31

Length: 8.40 min

Introduction of primary HPV screening in organized screening programs
J. Dillner (Sweden)

Content: Biography, Abstract, Video, Powerpoint

View the first minute

32

Length: 8.22 min

Implementation of HPV screening : national vs regional projects (organization, assessment, problems, solutions, results, communications) - Italy
G. Ronco (Italy)

Content: Abstract, Video, Powerpoint

View the first minute

33

Length: 7.36 min

Implementation of HPV screening : national vs regional projects (organization, assessment, problems, solutions, results, communications) - Germany
P. Hillemanns (Germany)

Content: Biography, Abstract, Video, Powerpoint

View the first minute

34

Length: 8.44 min

Implementation of HPV screening : national vs regional projects (organization, assessment, problems, solutions, results, communications) - Spain
S. Granado de la Orden (Spain)

Content: Video, Powerpoint

View the first minute

35

Length: 11.51 min

Implementation of HPV screening : national vs regional projects (organization, assessment, problems, solutions, results, communications)
Recommendation to introduce HPV-based screening in Belgium
M. Arbyn (Belgium)

Content: Biography, Video, Powerpoint

View the first minute



Course X
Management & control of HPV associated diseases - current knowledge and new horizons - a debate
Free access
36

Length: 4.47 min

Cervix- HPV screening in non-vaccinated women
N. Wentzensen (USA)

Content: Abstract, Video

View

37

Length: 4.42 min

Cervix- HPV screening in vaccinated women
K Canfell (Australia)

Content: Video

View

38

Length: 5.56 min

Cervix- Role of HPV in the management of abnormal Pap & CIN
M. Einstein (USA)

Content: Video

View

39

Length: 4.47 min

Cervix- Role of HPV in the management of abnormal Pap & CIN
M. Arbyn (Belgium)

Content: Biography, Video

View

40

Length: 1.17 min

Anus
How HPV knowledge has changed our pratice: screening and management of neoplastic lesions
C. Fairley (Australia)

Content: Video

View

41

Length: 5.35 min

Anus
How HPV knowledge has changed our pratice: screening and management of neoplastic lesions
M. Bower (UK)

Content: Video

View

42

Length: 5.52 min

Positioning the value of the new HPV vaccine
M. Jit (UK)

Content: Biography, Abstract, Video

View

43

Length: 3.38 min

Utility of cervical cancer screening in the era of multivalent and therapeutic vaccines
P. Gravitt (USA)

Content: Biography, Abstract, Video

View

44

Length: 2.11 min

Impact of prophylactic HPV vaccine in cancers other than cervical cancer
M. Brisson (Canada)

Content: Biography, Video

View

45

Length: 8.29 min

Discussion

Content: Video

View



Course XI
New insights in cervical cancer control
Buy an access only to the
Course XI for 1 Month
46

Length: 12.50 min

Community randomized HPV vaccination trial of the best vaccination strategy
M. Lehtinen (Finland)

Content: Abstract, Video, Powerpoint

View the first minute

47

Length: 19.15 min

The efficacy rates against CIN3 obtained by the quadrivalent and the bivalent vaccine Phase III trials were not identical-Why?
J. Paavonen (Finland)

Content: Abstract, Video, Powerpoint

View the first minute

48

Length: 15.59 min

Screening approaches for vaccinated population: Compass trial
K Canfell (Australia)

Content: Abstract, Video, Powerpoint

View the first minute

49

Length: 15.27 min

How to integrate HPV vaccination programs and organized screening programs
P. Nieminen (Finland)

Content: Abstract, Video, Powerpoint

View the first minute

50

Length: 16.25 min

Addressing an unmet medical need using a 9-valent virus-like particle (VLP)-based HPV vaccine
A. Saah (USA)

Content: Video, Powerpoint

View the first minute



Course XII
Potential impact of the quadrivalent, bivalent and nonavalent HPV vaccines, and alternative HPV vaccination strategies
Buy an access only to the
Course XII for 1 Month
51

Length: 11.33 min

Impact of cross-protection on overall vaccination effectiveness against HPV-related diseases
H. Berkhof (Netherlands)

Content: Biography, Abstract, Video, Powerpoint

View the first minute

52

Length: 10.33 min

Alternative dosing schedules, WHO perspective
A.M. Hanao-Restrepo (Switzerland)

Content: Video, Powerpoint

View the first minute

53

Length: 11.08 min

Impact of the nonavalent vaccine on cervical screening
K. Canfell (Australia)

Content: Abstract, Video, Powerpoint

View the first minute







EUROGIN Conferences
EUROGIN Roadmaps
EUROGIN e-Congress
EUROGIN e-Learning

Educational platform on Human Papillomavirus associated Cancers

EUROGIN is a platform on education, training, scientific research, expertise and networking on Human Papillomavirus and associated cancers in both genital and non-genital sites.

Started in 1993 as a conference where scientific progress and clinical practice converge, EUROGIN shares translational research with an international scientific community, aiming at accelerating the reduction of the burden of HPV related cancers and their mortality.


The EUROGIN Educational Platform on HPV associated cancers offers a high standard of scientific contents provided by top international experts allowing to extend knowledge and share experience, with the purpose of advancing science and translational research, as well as ensuring best clinical practice.

The platform offers 4 educational channels:

- International live conferences offering world class contents and cutting edge research in basic and clinical science

- EUROGIN Roadmaps: publications in free access to a collection of reviews dedicated to advanced research and best practices

- EUROGIN e-Congress, an online version of the best talks of EUROGIN meetings made available after the live events in order to reach
  a larger international audience

- EUROGIN multilingual e-learning training courses intended for clinicians and aimed to enhance knowledge and education in the field.








Previous Events


EUROGIN Publications